AbbVie Acquires GUB-014295 Rights
AbbVie and Gubra A/S a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, announced a license agreement to develop GUB 014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity
“At AbbVie, we are focused on transforming the future of patient care in areas where significant unmet need persists,” said Robert A. Michael, chief executive officer, AbbVie. “Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company.”
GUB 014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB 014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety hormone, has been identified as a potential therapeutic target for the treatment of obesity given its role in activating signals to the brain that result in appetite suppression and the reduction of food intake, while also acting as an inhibitory signal to delay gastric emptying.
Under the terms of the agreement, AbbVie will lead development and commercialization activities of GUB 014295 globally. Gubra will receive $350 million in total upfront payment and will be eligible to receive up to $1.875 billion in development, commercial and sales milestone payments with tiered royalties on global net sales. The transaction closure is subject to regulatory approvals and other customary closing conditions.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.